arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Damora Therapeutics, Inc.

DMRA

$29.91 ▲ +0.02 (+0.05%) at close

8 Visible periods

21 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Damora Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $40.8M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -87.7% ↗

FCF / Share $-4.93 ↗

Trailing P/E 7.5x

Price / Book 0.2x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-209.84M

↓ -878.8% —

FCF / Share Free cash flow per share

$-4.93

↑ +69.3% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↓

Dividend History

Dividend / share · sourced from SEC filings

$0.00 Latest / share

FY 2018

FY 2019

$0.00

FY 2020

$0.00

FY 2021

FY 2022

FY 2023

$0.00

FY 2024

$0.00

FY 2025

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
EPS Growth YoY (%)	N/M	48.6% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	40.6% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-18.5% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	-878.8% Weak ↓ Weak Declining Year-over-year change in net income	44.1% Excellent ↑ Excellent Improving Year-over-year change in net income	37.8% Excellent ↑ Excellent Improving Year-over-year change in net income	-19.1% Weak ↑ Weak Improving Year-over-year change in net income	-48.6% Weak Weak Year-over-year change in net income	4.6% Caution Caution Year-over-year change in net income	—	—
FCF Growth YoY (%)	69.3% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	53.7% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	18.2% Good Good Year-over-year change in free cash flow	18.4% Good Good Year-over-year change in free cash flow	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Effective Tax Rate (%) (%)	-0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.2% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
FCF / Net Income (x)	0.03x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.96x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.70x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.02x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	1.10x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	0.53x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Return on Invested Capital (%)	-87.7% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-140.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-123.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-99.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-44.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	20.3% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	-54.8% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-80.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-129.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-104.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-83.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-42.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	19.6% Excellent Excellent Operating profit relative to total assets Optimal: > 10%	68.8% Excellent Excellent Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-87.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-682%)	-135.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1003%)	-118.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-891%)	-99.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-765%)	-44.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-394%)	-21.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-240%)	51.3% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+242%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Net Debt (USD)	$-257.62M	$-14.18M	$-21.46M	$-32.79M	$-62.56M	$-163.58M	$-11.29M	—

📊 What does each share earn? 7 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Basic EPS, GAAP (USD)	$3.98	$-18.53	$-36.08	$-60.75	$-51.25	—	—	—
Free Cash Flow per Share (USD)	$-4.93	$-16.09	$-34.73	$-42.43	$-51.99	—	—	—
Dividend per Share (USD)	$0.00	$0.00	—	—	$0.00	$0.00	—	—
Book Value per Share (USD)	$150.49	$12.02	$29.81	$60.18	$116.01	$163.77	$-6.84K	—
Tangible Book Value per Share (USD)	$150.49	$12.02	$29.81	$60.18	$116.01	$163.77	$-6.84K	—
Basic Weighted Avg Shares (shares)	1.36M	1.16M	1.06M	1.02M	1.01M	—	—	—
Dividend Payout Ratio (%)	0.0% Excellent Excellent Dividends paid as a percentage of earnings Optimal: 30-60%	0.0% Excellent Excellent Dividends paid as a percentage of earnings Optimal: 30-60%	—	—	0.0% Excellent Excellent Dividends paid as a percentage of earnings Optimal: 30-60%	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Working Capital (USD)	$240.36M	$15.64M	$30.94M	$52.80M	$105.56M	$163.73M	$48.15M	—
Total Equity (USD)	$240.38M	$15.83M	$32.33M	$61.75M	$117.22M	$165.49M	$-71.15M	$-33.84M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Depreciation Expense (USD)	$22.00K	$21.00K	$269.00K	$42.00K	$20.00K	—	—	—
Net Income, GAAP (USD)	$-209.84M	$-21.44M	$-38.35M	$-61.62M	$-51.75M	$-34.84M	$-36.51M	—
Operating Cash Flow (USD)	$-6.73M	$-18.62M	$-36.91M	$-42.93M	$-52.31M	$-38.20M	$-19.33M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 29 quarters

Damora Therapeutics, Inc.

Analytical Summary

8-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Dividend History

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare DMRA with peers